Patent ID: 11946056
Assignee: ELIGO BIOSCIENCE
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  Y | IPC A  C

Claim 14:
15. A method of treating a subject infected with pathogenic or virulent bacteria comprising the administration of a pharmaceutical or veterinary composition of an engineered vector for DNA delivery into a group of bacteria of interest, said engineered vector being an engineered bacteriophage, packaged phagemid, bacteriophage genome or phagemid, which has been genetically engineered to remove, in non-coding regions and optionally in coding regions, at least one restriction site of at least one restriction enzyme which is frequently encoded in said group of bacteria of interest, wherein said at least one restriction site is removed by changing the sequence so as to prevent the recognition by the corresponding restriction enzyme and wherein the efficiency of DNA delivery into the group of bacteria by the engineered vector is increased as compared to DNA delivery into the group of bacteria by the engineered vector prior to removal of the at least one restriction site.